Restaging Pancreatic Cancer After Systemic Therapy: Scoping Review of CT, PET/CT, and CA19-9

No CT or PET/CT restaging method consistently predicted both R0 resection and survival in localized pancreatic cancer after systemic therapy across 20 studies; RECIST 1.1 is limited for partial response and stable disease. Integrating CA19-9 may improve accuracy.

• Most included studies (15/20) assessed CT-based methods; 5 assessed PET/CT.
• Dual-energy CT-derived extracellular volume (DECT-ECV) was evaluated as a baseline predictive biomarker, though associations were inconsistent.
• Incorporating the serum biomarker CA19-9 may reduce the risk of missed treatment options during restaging.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.